GJA1 and Schnyder corneal dystrophy: Platelet functionality was also altered, as heme treatment or Cx43 inhibition in MSCs led to a reduced platelet aggregation ability, potentially contributing to the heightened bleeding risk that occurs in patients with SCD (43).